Back to Search
Start Over
Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells
- Source :
- Journal of Neuroinflammation
- Publication Year :
- 2015
-
Abstract
- Background The purpose of this research was to validate the low expression of L-selectin (CD62L) in natalizumab (NTZ)-treated patients. CD62L is involved in rolling and transmigration of leukocyte cells. A correlation between CD62LCD4+ T cells low expression and progressive multifocal leukoencephalopathy (PML) development has been suggested in multiple sclerosis (MS) patients treated with NTZ. Methods We performed a flow cytometric analysis on peripheral blood mononuclear cells (PBMC); we collected from 23 healthy donors and 225 MS patients: untreated (n = 19) or treated with NTZ (n = 113), interferon-beta (n = 26), glatiramer acetate (n = 26), fingolimod (n = 23) and rituximab (n = 18). We have also analysed two PML/IRIS (immune reconstitution inflammatory syndrome) patients and four longitudinal samples of a NTZ-treated patients before and during the development of a clinical asymptomatic magnetic resonance imaging (MRI) lesion confirmed as PML by cerebrospinal fluid (CSF) examination. Thirty-five NTZ-treated patients were studied longitudinally with three samples taken 4 months apart. Results The NTZ-treated patients showed a lower percentage of CD62L (33.68 %, n = 113) than first-line treated patients (44.24 %, n = 52, p = 0.0004). NTZ effect was already clear during the first year of treatment (34.68 %; p = 0.0184); it persisted in the following years and disappeared after drug withdrawal (44.08 %). Three percent of longitudinally analysed patients showed a percentage of CD62LCD4+ T cells under a hypothetical threshold and one patient with asymptomatic PML belongs to a group which expressed low percentage of CD62LCD4+ T cells. Conclusions Our research confirms that NTZ has a specific effect on CD62LCD4+ T cells consisting in decreasing of the number of positive cells. The low level of CD62L found in a clinically asymptomatic PML patient strengthens its potential usefulness as a biomarker of high PML risk in NTZ-treated patients. A larger study is required to better confirm the data. Electronic supplementary material The online version of this article (doi:10.1186/s12974-015-0365-x) contains supplementary material, which is available to authorized users.
- Subjects :
- CD4-Positive T-Lymphocytes
Male
Pathology
Monocyte
Gastroenterology
Monocytes
Leukocyte Count
Immunologic Factor
Natalizumab
Immune Reconstitution Inflammatory Syndrome
Multiple Sclerosi
L-Selectin
biology
General Neuroscience
Progressive multifocal leukoencephalopathy
Middle Aged
Fingolimod
Neurology
CD4-Positive T-Lymphocyte
L-selectin
Rituximab
Female
medicine.symptom
Human
medicine.drug
Adult
medicine.medical_specialty
Multiple Sclerosis
Immunology
Asymptomatic
Cellular and Molecular Neuroscience
Young Adult
Internal medicine
parasitic diseases
medicine
Humans
Immunologic Factors
CD62L
Glatiramer acetate
Aged
Neuroscience (all)
PML
business.industry
Fingolimod Hydrochloride
Multiple sclerosis
Research
IRIS
Glatiramer Acetate
Interferon-beta
medicine.disease
biology.protein
business
Subjects
Details
- ISSN :
- 17422094
- Volume :
- 12
- Database :
- OpenAIRE
- Journal :
- Journal of neuroinflammation
- Accession number :
- edsair.doi.dedup.....c4141bd878bda00216fbab7aa83b20da